Brief: Arrivent Biopharma Enters Exclusive License With Lepu Biopharma For Mrg007, An Antibody Drug Conjugate
22/01/2025 24:02
Jan 21 (Reuters) - Lepu Biopharma Co Ltd 2157.HK :
* ENTERS EXCLUSIVE LICENSE WITH LEPU BIOPHARMA FOR MRG007,
AN
ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF GASTROINTESTINAL
CANCERS
Source text: ID:nGNX8rlqWM
Further company coverage: 2157.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lepu Biopharma
See all newsChina's Lepu Biopharma H1 revenue rises 12.1% on higher drug sales
Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals
Brief: Lepu Biopharma Reports Positive Top-Line Results From Global Phase III Trial Of CMG901 (AZD0901)
Lepu Biopharma set to jump most in 7 months on FY profit forecast
Brief: Lepu Biopharma Expects FY Net Profit Attributable